A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tuca
Principal Investigator
Study Number
STUDY02001120
Summary
This study is for patients who have human epidermal growth factor receptor 2 positive (HER2+) breast cancer and have already received treatment with chemotherapy, anti-HER2 therapies, and surgery. The usual treatment for these patients after surgery is an intravenous drug called T-DMI. All participants in this study will receive the usual treatment for this type of cancer. Half of the participants will also receive an additional, investigational treatment called tucatinib. Tucatinib is not FDA-approved for this use. Researchers hope to learn if combining tucatinib with T-DMI is better than the usual treatment of T-DMI alone at preventing this type of breast cancer from returning.
Phase
III
Contact
Available at the following location(s)
- Lebanon
View more details at ClinicalTrials.gov
Do you need help with some of the labels on this page?
Read our glossary of terms